News & Events

Exonics Therapeutics Announces Publication of Research Demonstrating Gene Repair Technology Corrected Cardiac Abnormalities Associated with Duchenne Muscular Dystrophy
SingleCut CRISPR efficiently restored dystrophin expression in human engineered heart muscle and demonstrated broad applicability across a range of Duchenne mutations. Study published online in the journal Science Advances.  
Exonics Therapeutics Appoints Roger M. Perlmutter, M.D., Ph.D., to Board of Directors
Dr. Perlmutter brings extensive biopharmaceutical research and development experience to Exonics’ board. Since 2013, Dr. Perlmutter has served as executive vice president of Merck and president of Merck Research Laboratories.  
Exonics Therapeutics Announces Publication of Research Demonstrating Gene Repair Technology Corrected Dystrophin Expression in Mouse Model of Duchenne Muscular Dystrophy
Exonics Therapeutics today announced the publication of a preclinical study demonstrating the Company’s SingleCut CRISPR technology efficiently corrected in vivo dystrophin expression in a mouse model of Duchenne.  
Exonics Therapeutics Raises $40 Million in Series A Financing
Funds to support continued development of SingleCut CRISPR technology for Duchenne muscular dystrophy  
NBC’s Sunday Night with Megyn Kelly
Watch Exonics’ scientific founder Dr. Eric Olson discuss the promise of gene editing for Duchenne muscular dystrophy  
The Great Hope / A Doctor’s Dilemma Documentary
Watch Dr. Olson and patient Ben Dupree discuss the potential of Exonics’ gene-editing therapy for Duchenne in this two-part German documentary on gene editing  
A CRISPR/Cas9 Startup Launches on the R&D Frontier, Working on a One-time Fix for Duchenne MD
Endpoints News  
Exonics to Use CRISPR in an Effort to Treat Majority of DMD Boys
FierceBiotech   
Startup Aims to Treat Muscular Dystrophy with CRISPR
MIT Technology Review  
Exonics Therapeutics Launches with Funding from CureDuchenne Ventures to Advance CRISPR/Cas9 Therapy for Duchenne Muscular Dystrophy
Exonics to develop a therapeutic approach to correct underlying genetic mutations in Duchenne, a degenerative genetic disorder without effective treatment options to halt progression of disease.